In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab′)

There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)₂, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2019-07, Vol.220 (1), p.41-45
Main Authors: Racine, Trina, Denizot, Mélanie, Pannetier, Delphine, Nguyen, Ludovic, Pasquier, Anaïs, Raoul, Hervé, Saluzzo, Jean-François, Kobinger, Gary, Veas, Francisco, Herbreteau, Cécile H.
Format: Article
Language:English
Subjects:
VIRUSES
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is no vaccine or approved therapy against lethal Ebola virus (EBOV). We investigated a proven technology platform to produce polyclonal IgG fragments, F(ab′)₂, against EBOV. Horses immunized with nanoparticles harboring surface glycoprotein trimers of EBOV-Zaire/Makona produced anti-Ebola IgG polyclonal antibodies with high neutralization activity. Highly purified equine anti-Ebola F(ab′)₂ showed strong cross-neutralization of 2 Zaire EBOV strains (Gabon 2001 and Makona) and in vivo 3 or 5 daily F(ab′)₂ intraperitoneal injections provided 100% protection to BALB/c mice against lethal EBOV challenge. Rapid preparation of purified equine anti-Ebola F(ab′)₂ offers a potentially efficient therapeutic approach against EBOV disease in humans.
ISSN:0022-1899
1537-6613
DOI:10.1093/infdis/jiz068